Thrombotic antiphospholipid syndrome: From guidelines to clinical management.
Review published in Medicina clinica (2024)
Abstract
Thrombotic manifestations, mainly venous thromboembolism (VTE) and stroke, are the most common and potentially life-threatening presentations of antiphospholipid syndrome (APS). The management of APS requires the assessment of the antiphospholipid antibodies (aPL) profile, of concurrent systemic lupus erythematosus or other systemic autoimmune diseases and the presence of risk factors for cardiovascular disease and bleeding. Anticoagulation with vitamin K antagonists (VKA) remains the cornerstone of therapy for thrombotic APS. As platelets play a central role in APS, low-dose aspirin is the first option for primary thromboprophylaxis in asymptomatic aPL carriers, and also plays a role as combination therapy with VKAs in arterial thrombosis. Treatment with direct oral anticoagulants (DOACs) could be considered in certain low-risk situations, although they are not recommended in patients with arterial thrombosis or triple positive aPL. Adjuvant therapies such as hydroxychloroquine and statins may be useful in complex settings such as thrombotic recurrences or high risk of bleeding. In this article, we review the evidence and the recommendations of the guidelines for the treatment of APS, and provide a critical and practical approach of its management from our clinical perspective.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Thrombotic manifestations, mainly venous thromboembolism (VTE) and stroke, are the most common and potentially life-threatening presentations of antiphospholipid syndrome (APS). The management of APS requires the assessment of the antiphospholipid antibodies (aPL) profile, of concurrent systemic...
Warum dies für die Hirudotherapie relevant ist
Dieses Review behandelt das Management des thrombischen Antiphospholipid-Syndroms und diskutiert die Antikoagulation mit Vitamin-K-Antagonisten als Eckpfeiler, mit Rollen für Aspirin, direkten oralen Antikoagulanzien in ausgewählten Fällen sowie adjuvante Therapien wie Hydroxychloroquin und Statine. Es ist nur insofern für das ASH-Gebiet relevant, als es sich um den weiten Bereich der antikoagulativen Therapie handelt – den klinischen Raum, der auch mit Hirudin-Derivaten geteilt wird. Das Abstract nimmt keinerlei Bezug auf Blutegel, Hirudotherapie oder auf Hirudin-basierte Wirkstoffe. Die Verbindung zur Hirudotherapie ist indirekt und begrenzt.
Zitation
Thrombotic antiphospholipid syndrome: From guidelines to clinical management.
Paredes-Ruiz et al. · Medicina clinica, 2024
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026